Vanda Pharmaceuticals (VNDA) Enterprise Value (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Enterprise Value of -$202.3 million for Q1 2026, up 23.32% sequentially from -$263.8 million in Q4 2025, and up 40.66% YoY from -$143.8 million in Q1 2025.
Vanda Pharmaceuticals (VNDA) Enterprise Value (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Enterprise Value for 17 years, with the latest figure at -$202.3 million in Q1 2026.
- Quarterly Enterprise Value rose 40.66% year-over-year to -$202.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$202.3 million (up 40.66% YoY) and the FY2025 annual result came in at -$263.8 million, up 29.57% from the prior year.
- Enterprise Value advanced to -$202.3 million in Q1 2026 per VNDA's latest filing, from -$263.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$202.3 million in Q1 2026 and troughed at -$501.5 million in Q1 2023.
- A 5-year average of -$389.7 million and a median of -$388.3 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2026: Enterprise Value retreated 15.24% in 2023, then soared 40.66% in 2026.
- Over 5 years, Enterprise Value stood at -$466.9 million in 2022, then increased by 16.83% to -$388.3 million in 2023, then rose by 3.51% to -$374.6 million in 2024, then increased by 29.57% to -$263.8 million in 2025, then rose by 23.32% to -$202.3 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$202.3 million, -$263.8 million, and -$293.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | -170.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -170.03 Mn |
| Mar 31, 2026 | -202.31 Mn |
| Dec 31, 2025 | -263.85 Mn |
| Sep 30, 2025 | -293.75 Mn |
| Jun 30, 2025 | -325.55 Mn |
| Mar 31, 2025 | -340.91 Mn |
| Dec 31, 2024 | -374.64 Mn |
| Sep 30, 2024 | -376.26 Mn |
| Jun 30, 2024 | -387.68 Mn |
| Mar 31, 2024 | -394.14 Mn |
| Dec 31, 2023 | -388.26 Mn |
| Sep 30, 2023 | -489.86 Mn |
| Jun 30, 2023 | -489.35 Mn |
| Mar 31, 2023 | -501.50 Mn |
| Dec 31, 2022 | -466.86 Mn |
| Sep 30, 2022 | -454.79 Mn |
| Jun 30, 2022 | -440.86 Mn |
| Mar 31, 2022 | -435.18 Mn |
| Dec 31, 2021 | -432.81 Mn |
| Sep 30, 2021 | -405.97 Mn |